S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Sell every Stock except ONE (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Sell every Stock except ONE (Ad)
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Sell every Stock except ONE (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Sell every Stock except ONE (Ad)
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Sell every Stock except ONE (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Sell every Stock except ONE (Ad)
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Sell every Stock except ONE (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Sell every Stock except ONE (Ad)
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:ADXN

Addex Therapeutics - ADXN Stock Forecast, Price & News

$1.34
+0.05 (+3.88%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.16
$1.39
50-Day Range
$0.92
$3.85
52-Week Range
$0.86
$10.28
Volume
959,970 shs
Average Volume
9.10 million shs
Market Capitalization
$14.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Addex Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,019.4% Upside
$15.00 Price Target
Short Interest
Healthy
3.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.07mentions of Addex Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.06) to ($0.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

718th out of 1,117 stocks

Pharmaceutical Preparations Industry

358th out of 550 stocks

ADXN stock logo

About Addex Therapeutics (NASDAQ:ADXN) Stock

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Analyst Ratings Changes

Separately, HC Wainwright cut shares of Addex Therapeutics from a "buy" rating to a "neutral" rating in a research report on Thursday, June 23rd.

Addex Therapeutics Stock Up 3.9 %

NASDAQ:ADXN traded up $0.05 on Friday, reaching $1.34. 959,970 shares of the company's stock were exchanged, compared to its average volume of 9,100,535. The firm has a market capitalization of $14.58 million, a price-to-earnings ratio of -0.41 and a beta of 1.98. Addex Therapeutics has a 52-week low of $0.86 and a 52-week high of $10.28. The business has a fifty day moving average of $1.63 and a 200-day moving average of $3.71.

Receive ADXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADXN Stock News Headlines

Addex Completes $4.2 Million Equity Financing
Addex Raises $4.2 million in Equity Financing
Addex Completes Reduction in Nominal Value of Shares
Why Shares Of Addex Therapeutics Are Falling Today
Addex Reports Q1 2022 Financial Results
Addex to Present at the Swiss Biotech Day 2022
See More Headlines
Receive ADXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADXN Company Calendar

Last Earnings
11/04/2021
Today
8/13/2022
Next Earnings (Confirmed)
8/18/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADXN
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+1,019.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-16,800,000.00
Net Margins
-748.78%
Pretax Margin
-749.29%

Debt

Sales & Book Value

Annual Sales
$3.45 million
Book Value
$2.26 per share

Miscellaneous

Free Float
N/A
Market Cap
$14.58 million
Optionable
Not Optionable
Beta
1.98

Key Executives

  • Mr. Timothy Mark Dyer (Age 54)
    Co-Founder, CEO & Director
  • Dr. Roger G. Mills M.D. (Age 65)
    Chief Medical Officer & Director
  • Mr. Lénaic Teyssédou (Age 36)
    Head of Fin.
  • Dr. Jean-Philippe Rocher Ph.D. (Age 63)
    Head of Discovery - Chemistry
  • Dr. Robert Lutjens (Age 54)
    Head of Discovery - Biology
  • Dr. Mikhail Kalinichev Ph.D. (Age 54)
    Head of Translational Science
  • Dr. Werner Henrichi Ph.D. (Age 79)
    Consultant













ADXN Stock - Frequently Asked Questions

Should I buy or sell Addex Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Addex Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADXN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXN, but not buy additional shares or sell existing shares.
View ADXN analyst ratings
or view top-rated stocks.

What is Addex Therapeutics' stock price forecast for 2022?

1 brokerages have issued 1-year target prices for Addex Therapeutics' shares. Their ADXN share price forecasts range from $15.00 to $15.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 1,019.4% from the stock's current price.
View analysts price targets for ADXN
or view top-rated stocks among Wall Street analysts.

How have ADXN shares performed in 2022?

Addex Therapeutics' stock was trading at $6.29 at the start of the year. Since then, ADXN shares have decreased by 78.7% and is now trading at $1.34.
View the best growth stocks for 2022 here
.

When is Addex Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 18th 2022.
View our ADXN earnings forecast
.

How were Addex Therapeutics' earnings last quarter?

Addex Therapeutics Ltd (NASDAQ:ADXN) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.72) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.72). The company had revenue of $0.83 million for the quarter, compared to the consensus estimate of $0.42 million. Addex Therapeutics had a negative trailing twelve-month return on equity of 123.92% and a negative net margin of 748.78%. During the same period last year, the company posted ($0.78) earnings per share.

What other stocks do shareholders of Addex Therapeutics own?

What is Addex Therapeutics' stock symbol?

Addex Therapeutics trades on the NASDAQ under the ticker symbol "ADXN."

Who are Addex Therapeutics' major shareholders?

Addex Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include OLD Mission Capital LLC (0.29%).

How do I buy shares of Addex Therapeutics?

Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Addex Therapeutics' stock price today?

One share of ADXN stock can currently be purchased for approximately $1.34.

How much money does Addex Therapeutics make?

Addex Therapeutics (NASDAQ:ADXN) has a market capitalization of $14.58 million and generates $3.45 million in revenue each year. The company earns $-16,800,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis.

How can I contact Addex Therapeutics?

Addex Therapeutics' mailing address is CHEMIN DES AULX 12 PLAN-LES-OUATES, GENEVA V8, CH-1228. The official website for the company is www.addextherapeutics.com. The company can be reached via phone at 41-22-884-1555, via email at investor.relations@addextherapeutics.com, or via fax at 41-22-884-1556.

This page (NASDAQ:ADXN) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.